Amado Andrés

Amado Andrés is presented as a nephrologist whose professional identity is tied to the Spanish transplantation system and to the clinical problem of hepatitis C in renal transplantation. He is listed among the authors of a chapter on renal transplantation from donors with positive hepatitis C serology, alongside Beatriz Domínguez-Gil, Nuria Esforzado, and Josep M. Campistol, with an affiliation to the Nephrology Department of Hospital 12 de Octubre in Madrid. His documented role is therefore not that of a fictional protagonist but of a clinical expert participating in the construction, assessment, and application of transplant evidence.

Identity and Professional Setting

Amado Andrés appears within an institutional network rather than through personal biography or dramatic action. The author listing places him in the Nephrology Department of Hospital 12 de Octubre, Madrid, and connects him to Organización Nacional de Trasplantes through the chapter’s wider authorship structure. That setting matters because the subject of the work is inseparable from allocation systems, waiting lists, donor evaluation, recipient selection, and long-term graft surveillance. Andrés is thus associated with a form of medicine in which an individual patient’s opportunity for transplantation is negotiated through epidemiological risk and limited public resources.

The chapter in which he appears examines kidneys from HCV-positive donors, a category treated as nonstandard because hepatitis C can be transmitted through organ transplantation. The evidence describes substantial international variation: many centers refuse such kidneys, while some countries impose technical or legal prohibitions. Andrés’s scholarly identity is consequently linked to a contested boundary between safety and opportunity. The question is not merely whether an infected organ carries a hazard, but whether discarding it is defensible when demand for kidneys greatly exceeds supply.

Work on HCV and Kidney Transplantation

The central clinical problem associated with Andrés’s contribution is the management of HCV-positive recipients who face end-stage renal disease and prolonged dialysis. The chapter notes that organ transplantation benefits about 100,000 patients worldwide each year, yet the available supply remains far below demand. At the end of 2009, approximately 63,000 people were on an organ waiting list in the European Union while only 28,000 transplant procedures were performed during that year; in the United States, almost 111,000 candidates were registered in May 2011 against roughly 28,000 procedures annually. These figures establish the pressure under which the use of HCV-positive kidneys must be judged.

Within this scarcity, kidneys from HCV-positive donors may become surplus organs because suitable HCV-positive recipients are less common than in earlier periods. Expanded HCV treatment, preventive strategies, and declining active infection among patients with end-stage renal disease have reduced the pool of infected candidates. Andrés’s associated evidence emphasizes that the result can be paradoxical: while patients continue to wait for kidneys, potentially usable HCV-positive organs are discarded. Donated HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys, making organizational policy a decisive part of the clinical problem.

The evidence also records a long-term study by Morales, Campistol, Domínguez-Gil, Andrés, Esforzado, and colleagues on kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. This work places Andrés within an extended effort to evaluate outcomes beyond the immediate operation. The relevant comparison is between the foreseeable consequences of donor-derived or intensified HCV infection and the harms of remaining on dialysis while waiting for a conventional organ. The chapter’s position is that transplantation may offer a more favorable course than continued dialysis for some HCV RNA-positive patients, even when antiviral treatment is unavailable, refused, unsuccessful, discontinued, prolonged, or unaffordable.

Clinical Judgment and Competing Risks

Andrés’s documented clinical framework does not treat HCV status as a single, self-explanatory category. Candidates may be screened for anti-HCV antibodies and, where appropriate, active viremia by nucleic acid testing. Before transplantation, liver disease must be staged, with liver biopsy remaining the gold standard for identifying advanced injury in patients with active HCV infection. Studies cited in the surrounding transplant evidence found advanced liver injury, including stage 3 or 4 disease, in 10–25% of pre-kidney-transplant candidates who underwent biopsy. Patients with established or decompensated cirrhosis should be referred for consideration of simultaneous liver–kidney transplantation rather than treated as ordinary kidney-alone candidates.

The waiting list creates a second temporal risk. Patients with active infection may remain listed for years, and in some United States centers the waiting period approaches five to seven years. Candidates who remain viremic therefore require regular assessment for progression of liver disease. In one follow-up group, 8 of 13 patients, or 62%, showed worsening liver histology while still waiting, compared with 7 of 31, or 23%, whose biopsies worsened after transplantation. These figures sharpen the practical dilemma associated with Andrés’s work: delay is not neutral, because dialysis and waiting can permit liver disease to advance while the patient remains exposed to the mortality and morbidity of end-stage renal disease.

Antiviral therapy before transplantation may produce a sustained virological response and may reduce the risk of post-transplant diabetes or immune-complex-mediated glomerular disease, but the treatment itself has limitations. Interferon can cause a wide range of adverse events; nonresponse is common enough to matter; treatment is lengthy and expensive; and candidates may have to be excluded from the waiting list during therapy. In contrast, post-transplant interferon is associated with increased allograft rejection, so efforts to eradicate HCV are preferably concentrated before transplantation. This balance explains why an HCV-positive kidney may remain a rational option for a patient who cannot undergo effective pretransplant antiviral treatment.

Institutional Networks and Responsibility

Although Andrés is named as an author rather than described as a bedside actor, his professional significance emerges from the networks that organize HCV care. Screening laboratories distinguish antibody exposure from active viremia; hepatologists assess liver injury; transplant teams determine whether kidney-alone or combined liver–kidney transplantation is appropriate; waiting-list systems monitor candidates; and organ procurement organizations determine whether a positive-serology kidney is offered or discarded. The patient’s body is therefore translated into a sequence of classifications and decisions, each carrying consequences for access to transplantation.

The same institutional logic appears in dialysis infection control. Molecular studies of HCV isolates from patients treated in the same hemodialysis unit demonstrated clusters of closely related viral strains, supporting nosocomial transmission even when the precise route could not be reconstructed. In a systematic review of 20 studies, none conclusively established the exact transmission route, but all implicated failures in infection-control procedures. In 18 of the 20 studies, some or all newly infected patients had not shared a dialysis machine with the source patient, suggesting that the internal machine circuit played, at most, a small role. These findings reinforce a principle relevant to Andrés’s transplant work: risk must be located in actual systems of contact and practice, not assigned automatically to a single device or status label.

The recommended response to dialysis transmission is strict infection control rather than routine isolation. Staff should wash their hands before and after contact with patients or equipment, use disposable gloves when touching patients or potentially contaminated surfaces, discard single-use items, disinfect nondisposable equipment, and clean dialysis-station surfaces after every session. Observational audits are also recommended because formal consensus does not guarantee compliance. The contrast between the relatively weak protection offered by isolation and the central importance of everyday hygiene illustrates the broader ethical issue in Andrés’s field: institutional convenience must not substitute for evidence-based prevention.

Narrative and Medical Significance

Amado Andrés’s significance lies in the way his professional work frames transplantation as a decision under competing forms of vulnerability. HCV infection can be clinically silent in long-term dialysis, while biochemical abnormalities may be overlooked amid hypertension, gastrointestinal bleeding, anemia, vascular-access failure, and other comorbidities. At the same time, HCV-positive dialysis patients may experience reduced mental quality of life; in one study, anti-HCV-positive status was independently associated with a lower mental component summary score on the SF-36, even though no association with the physical component score was found. The medical problem therefore includes not only viral transmission and liver histology but also the psychological burden of diagnosis and prolonged treatment.

Against this background, Andrés is associated with a pragmatic but conditional argument: HCV-positive kidneys should not be wasted automatically when they can shorten waiting time for appropriately selected HCV-positive recipients. The proposal does not erase the danger of HCV transmission, nor does it make donor serology irrelevant. It instead places that danger beside dialysis mortality, waiting-list deterioration, antiviral toxicity, financial barriers, and the possibility that a patient will never receive a conventional kidney. His role in the evidence is to help articulate transplantation as neither unconditional acceptance nor categorical exclusion, but as a structured clinical judgment in which the risks of an organ, the risks of delay, and the availability of treatment must be considered together.